

## **Supplementary Materials**

### **1. Supplementary experimental procedures:**

**Hepatic Secretion of very low-density lipoprotein (VLDL)-TG.** To estimate the rate of VLDL-TG secretion from the liver, mice were intraperitoneally injected with 500 mg/kg of tyloxapol (Sigma-Aldrich T0307), an inhibitor of lipoprotein lipase (LPL)[1]. Blood samples were collected from the tail vein 30 min before (time 0) and at 2, 3, and 4 h after injection. The TG concentration was determined with commercial colorimetric kits (Biolabo SAS, Maizy, France, #87656 #87319) based on the CHOD-PAP and GPO-PAP detection methods, coupling enzymatic reaction, and spectrophotometric detection of reaction end products (Dyasis, Grabels France). The TG production rate for individual mice was, therefore, calculated using the linear increment between the baseline value and 4 h and expressed as mg/dL.


1. Duerden, J.M.; Gibbons, G.F. Secretion and storage of newly synthesized hepatic triacylglycerol fatty acids in vivo in different nutritional states and diabetes. *Biochem. J.* **1988**, 255, 929–935.

## 2. Supplementary Tables:


**Table S1:** List of qPCR primer pair sequences and GeneBank accession numbers specific to each gene.

Gene symbol	Forward primer (5'-3')	Reverse primer (5'-3')	GeneBank
<i>Gapdh</i>	TGCACCACCAACTGCTTAGC	GGCATGGACTGTGGTCATGAG	NM_001289726
<i>Pgc-1α</i>	AAAGGATGCGCTCTCGTTCA	GGAATATGGTATCGGGAAACA	NM_008904
<i>Ucp1</i>	CCTGCCTCTCGGAAACAA	TGTAGGCTGCCAATGAACA	NM_009463
<i>Prdm16</i>	CAGCACGGTAAGCCATT	GCGTGCATCCGCTTGTG	NM_001291026
<i>Cidea</i>	GCCGTGTTAAGGAATCTGCTG	TGCTCTCTGTATCGCCCAGT	NM_007702
<i>Cd36</i>	GCGACATGATTAATGGCACAGACG	TCCGAACACACGGTAGATAGACC	NM_001159558.1
<i>Acox1</i>	CTATGGGATCAGCCAGAAAG	AGTCAAAGGCATCCACCAAAG	NM_0015729.4
<i>Cpt1-a</i>	CACCAACGGGCTCATCTTCT	CCTTCTATCGAATTGCTCTGGTT	NM_013495
<i>Acaca</i>	AGCAACATCACATCAGCCTGT	CAGTGTAGCTGCATGACTATCTAGG	NM_13360.3
<i>Elovl6</i>	TCTGATGAACAAGCGAGCCA	TGGTCATCAGAACATGTACAGCATGT	NM_130450
<i>Pparα</i>	CCCTGTTGTGGCTGCTATAATT	GGGAAGAGGAAGGTGTACATCTG	NM_011144
<i>Ehhadh</i>	TTGGACCATAACGGTTAGAGCC	GGATATCAGCACCTGCACAGA	NM_023737.3
<i>Acaa1</i>	ACATCTCCGTGGCAATGTT	CTCAGAAATTGGGCGATGCG	NM_001357516.1
<i>Atgl</i>	TCCTTAGGAATGCCCTAC	TCCTCTCCTGGGGACAAC	NM_001163689.1
<i>Hsl</i>	GATGCCATGTTGCCAGAGAC	ACTTCTCGAAAGCCTCTGGAACA	XM_030242180.1
<i>Srebp1c</i>	CTGGCTTGGTGATGCTATGTT	GACCATCAAGGCCCCCTCAA	NM_001358315
<i>Fas</i>	CGGCTGCGTGGCTATGATTATG	GCAGCTTGCCTGTTCACCTTC	NM_007988
<i>Scd1</i>	CGTGGGCCCGGTGAT	CAACACCATGGCGTCCA	NM_009127.4
<i>Elovl3</i>	GGACCTGATGCAACCTATGA	TCCGCGTTCTCATGTAGGTCT	NM_007703
<i>Dgat</i>	GGCGGTCCCCAACCAT	AGACAGGAGTGGAAAAACCAATAGA	NM_010046.3
<i>Mtp</i>	TCAGGAAGCTGTGTCAGAATGAAG	TTTCAAGTCCTCCCAGGATCA	NM_008642
<i>Srebp2</i>	CTGCAGCCTCAAGTGCAAAG	CAGTGTGCCATTGGCTGTCT	NM_033218
<i>Hmgs1</i>	TGCATAGTAACACAGCAACAGAGC	TGCAGGGAGTCTGGCACTTTC	NM_001291439.1
<i>Hmgcr</i>	CCGGCAACAAACAAGATCTGTG	ATGTACAGGATGGCGATGCA	NM_001360165
<i>Scarb1/Srb1</i>	CGCCGACCCCTGTGTTGTC	GGATGTCTAGGAACAAGGAATGCT	NM_001205083
<i>Ldlr</i>	GCATCAGCTTGGACAAGGTGT	GGGAACAGCCACCAATTGTTG	NM_010700
<i>Vldlr</i>	TCCTGATTGCGAAGACGGTTCTG	ATGCGCATGTTCTCATATGGC	NM_001347441.1
<i>Abca1</i>	ATCGTGTCTGCCTGTTCTCA	GTCCTTAATGCTGGTATCTTTGG	NM_013454
<i>Cyp7A1</i>	CAGGGAGATGCTGTGTTCA	AGGCATACATCCCTCCGTGA	NM_007824
<i>Cyp27A1</i>	GCCTCACCTATGGATCTTCA	TCAAAGCCTGACCGAGATG	NM_024264
<i>Abcg5</i>	GGATCCAACACCTCTATGCTAAA	GGCAGGTTTCTCGATGAACGT	NM_031884
<i>Abcg8</i>	ATCCATTGCCACCCCTGT	GCGTCTGTCGATGCTGGTC	NM_026180


**3. Supplementary figures:**




**Figure S1. Effect of intermittent fasting in *Apoe*<sup>-/-</sup> mice on metabolic efficiency.** (A-B) Metabolic efficiency was calculated as g of body weight gained per MJ of food consumed during the 16 weeks of intervention for *ad libitum* (AL) or intermittent fasting (IF) CD-fed mice (A) and HFCD-fed mice (B). Data are presented as means  $\pm$  SEM (n = 12–14 per group); ns; not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



**Figure S2. Effect of intermittent fasting in *Apoe<sup>-/-</sup>* mice on the plasma insulin level during glucose tolerance test.**  
 (A–D) Plasma insulin concentration at the indicated times after intraperitoneal bolus injection of glucose to fasted *ad libitum* (AL, white bars) or intermittent fasting (IF, grey bars) CD-fed males (A), CD-fed females (B), HFCD-fed males (C), and HFCD-fed females (D). Data are presented as means  $\pm$  SEM (n = 5–9 per group); ns; not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



**Figure S3. Effect of intermittent fasting in *Apoe*<sup>-/-</sup> mice on white and brown adipose tissue weight.** (A,B) Subcutaneous white adipose tissue (SC-WAT) weights relative to body weight of *ad libitum* (AL) or intermittent fasting (IF) CD-fed mice (A) and HFCD-fed mice (B). (C,D) Brown adipose tissue (BAT), weights relative to body weight of *ad libitum* (AL) or intermittent fasting (IF) CD-fed mice (C) and HFCD-fed mice (D). Data are presented as means  $\pm$  SEM (n = 6–10 per group); ns; not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



**Figure S4. Effect of intermittent fasting in *Apoe*<sup>-/-</sup> mice on hepatic very low-density-lipoprotein (VLDL)-TG secretion.** (A–D) Hepatic VLDL-TG secretion assessed at the indicated times following lipoprotein lipase inhibition by injecting 500 mg/kg of tyloxapol after a 4 h fast of *ad libitum* (AL) or intermittent fasting (IF) mice. Left panel: change in plasma VLDL-TG concentration for the indicated times, Right panel: rate of VLDL-TG secretion at 4 h. CD-fed males (A), CD-fed females (B), HFCD-fed males (C), HFCD-fed females (D). Data are means  $\pm$  SEM ( $n = 6$  per group); ns; not significant, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .